WAVEMAN · COMPANY

GILD · Gilead Sciences, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

GILD

Name: GILEAD SCIENCES, INC. (GILD) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

GILEAD SCIENCES, INC.

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0000882095

CONGRESS · 2FORM 144 · 7☆ WATCH

INSIDER NET · 180D

-$25.7M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

1,111

13F, latest reported quarter

REVENUE GROWTH

+2.4%

XBRL, annual

NET MARGIN

28.9%

CONVERSIONS · 180D

codes C/M, not in net · $4.8M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$25.7M over 180 days

-$15.3M over 90 days

below 90% of Pharma & Biotech

CONGRESS

2 members bought in the last year

more than 65% of Pharma & Biotech

FUNDS

1,111 funds added or opened last quarter

more than 99% of Pharma & Biotech

REVENUE

+2.4% year over year

more than 50% of Pharma & Biotech

MARGIN

28.9% net margin

more than 92% of Pharma & Biotech

BUYBACKS

$774.0M repurchased, FY to 2026-06-30

more than 92% of Pharma & Biotech

SHORT

2.0% of shares outstanding short · 3.9 days to cover · settled 2026-07-31

below 64% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$25.7M across 5 people in 180 days.

1,111 funds added or opened positions in the latest 13F quarter, of 2,285 holders.

2 members of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +37.5%

+37.5%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $25.7M sold by insiders over 180 days, 1,111 funds added last quarter, 2 Congress member(s) bought in 12 months, $15.6M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, GILEAD SCIENCES, INC. insiders sold a net $25.7M of stock across 143 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

O'Day Daniel Patrick

Chairman & CEO

SELL

2026-09-01

1,600.0

$236.0K

O'Day Daniel Patrick

Chairman & CEO

SELL

2026-09-01

7,992.0

$1.2M

O'Day Daniel Patrick

Chairman & CEO

SELL

2026-09-01

5,408.0

$807.9K

WELTERS ANTHONY

Director

SELL

2026-08-26

3,118.0

$462.4K

WELTERS ANTHONY

Director

SELL

2026-08-26

4,600.0

$684.6K

143 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 138 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

121,844,108.0 sh

$15.4B

VANGUARD CAPITAL MANAGEMENT LLC

81,091,734.0 sh

$10.2B

FMR LLC

66,870,816.0 sh

$8.4B

STATE STREET CORP

61,216,552.0 sh

$7.7B

Capital World Investors

40,988,975.0 sh

$5.2B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

ANTHONY WELTERS

FILED 2026-08-26

$2.7M

JEFFREY BLUESTONE

FILED 2026-08-20

$738.0K

ANDREW DICKINSON

FILED 2026-08-17

$415.1K

JOHANNA MERCIER

FILED 2026-08-17

$3.9M

DANIEL O'DAY

FILED 2026-08-03

$7.2M

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

VanEck Biotech ETF

$54.4M POSITION · AS OF 2026-03-31

14.6%

Invesco Nasdaq Biotechnology ETF

$7.3M POSITION · AS OF 2026-02-28

9.6%

Select Biotechnology Portfolio

$469.2M POSITION · AS OF 2026-02-28

8.8%

iShares Biotechnology ETF

$629.4M POSITION · AS OF 2026-03-31

7.7%

AlphaCentric Life Sciences and Healthcare Fund

$2.8M POSITION · AS OF 2026-03-31

7.2%

ProShares Ultra Nasdaq Biotechnology

$5.9M POSITION · AS OF 2026-02-28

6.5%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 138 registered trials, 67 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

13 ACTIVE

Phase 2

20 ACTIVE

Phase 3

21 ACTIVE

Phase 4

1 ACTIVE

Not applicable

2 ACTIVE

Multi-phase

10 ACTIVE

What changed recently

Study of GS-0151 in Participants With Rheumatoid Arthritis

2026-09-04 · Recruiting → Active Not Recruiting

Phase 1

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamo

2026-09-04 · Completion moved 2026-08 → 2027-03

Phase 2

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Rem

2026-09-02 · Recruiting → Active Not Recruiting

Phase 2

Study of GS-0415 and How It Works in People With HIV

2026-09-02 · Not Yet Recruiting → Recruiting

Phase 1

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Gilead Sciences Inc Healthcare Policy Pac

CYCLE 2026 · $733K SPENT

$585.6K

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Executive pay vs shareholder return · Mr. O’Day

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$28.4M

$63.3M

$9.2M

+155%

+25%

2024

$23.7M

$44.8M

$7.7M

+87%

-7%

2023

$22.6M

$15.5M

$7.6M

+57%

-6%

2022

$21.6M

$55.0M

$7.9M

+61%

-10%

2021

$19.2M

$31.5M

$6.3M

+30%

+0%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$29.4B	$28.8B	$27.1B	$27.3B
OPERATING INCOME	$10.0B	$1.7B	$7.6B	$7.3B
NET INCOME	$8.5B	$480.0M	$5.7B	$4.6B
EPS (DILUTED)	6.78	0.38	4.50	3.64
OPERATING CASH FLOW	$10.0B	$10.8B	$8.0B	$9.1B
CASH	—	—	—	$5.4B
LONG-TERM DEBT	$22.1B	$24.9B	$23.2B	$23.0B
BUYBACKS	$1.9B	$1.1B	$1.0B	$1.4B
DIVIDENDS PAID	$4.0B	$3.9B	$3.8B	$3.7B

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE